Table 2

Changes in physical examination, echocardiography and functional status 6 months after initiation of sacubitril/valsartan treatment, n=18

6 months
P value
NYHA class (n, %)0.112
 II13 (72%)15 (83%)
 III–IV5 (28%)3 (17%)
Systolic blood pressure (mm Hg)106±10106±140.960
Weight (kg)80±1879±180.187
6 min walking distance (m)564±104600±720.011*
Global RV function, (n, %)0.157
 Mildly reduced4 (22%)5 (28%)
 Moderately reduced10 (56%)10 (56%)
 Severely reduced4 (22%)3 (16%)
TAPSE (mm)12±211±20.211
RV FAC (%)19±722±7<0.001*
RV GLS (%)−11±3−13±20.014*
RVEDD (mm)59±958±80.067
Tricuspid valve regurgitation (n, %)1.000
 Grade I–II15 (88%)15 (88%)
 Grade III–IV2 (12%)2 (12%)
LV GLS (%)−16±4−18±50.110
MAPSE (mm)18±518±30.663
Exercise testing
Exercise capacity (W)129±50132±470.402
Exercise capacity (%)79±1781±170.575
VO2max (ml/min/kg)18±518±40.886
% of predicted VO2max achieved59±1558±130.746
% of predicted heart rate achieved77±1378±140.717
Heart rate reserve (bpm)66±2465±260.795
  • *Statistically significant.

  • bpm, beats per minute; FAC, fractional area change; GLS, global longitudinal strain; LV, (subpulmonary) left ventricle; MAPSE, mitral annular plane systolic excursion; NYHA, New York Heart Association functional classification; RER, respiratory exchange ratio; RV, (systemic) right ventricle; RVEDD, (systemic) right ventricular end diastolic diameter (basal measurement); ; TAPSE, tricuspid annular plane systolic excursion.